A2-73 outperformed DPZ. It's clearly demonstrated in the 31 week data. You're behind on your DD
Looks like the patent was acquired last year.
NEW YORK, NY, August 12, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Pat. App. No. 14/205,637 related to ANAVEX 2-73. Upon issuance, the patent will provide intellectual property (IP) protection until at least 2035. ANAVEX2-73 is the subject of an ongoing Phase 2a clinical trial for the treatment of Alzheimer’s disease.
The allowed patent claims cover formulations and treatments that provide particular coverage relating to improved sigma receptor ligands and their use.
“This patent is a valuable addition to our IP portfolio and covers innovations we have made in our development efforts for ANAVEX 2-73 and beyond,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We have filed numerous patent applications to cover promising compositions and therapies, including those pertaining to ANAVEX 2-73, in keeping with our commitment to a comprehensive IP protection strategy.”
Additional U.S. patent applications filed for pharmaceutical composition of matter for ANAVEX 2-73 will, if granted, provide further patent protection until at least 2035. An additional patent application on file for ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil, if granted, will provide protection for composition of matter until at least 2033.
The USPTO issues a Notice of Allowance after it determines that a patent should be granted for a claimed invention that is novel in comparison to all known technology in existence. Based on the timing of this Notice of Allowance, Anavex expects the patent to be issued by the end of 2015.
My Price Targets:
$5 Labor Day
Catalysts: Updates on any of the following Neurodegenerative Disease Pipeline:
ALZ Phase 2a, Part B 52-week data
ALZ Phase 2/3 announcement
ALZ Phase 2/3 partnership
Schizophrenia with Cognitive Impairment
Because a BP is going to fund Phase 3?
The A2-73 data has effectively put DPZ out of business, and since DPZ is the SOC, A2-73 is on a track to becoming the new SOC.
Thank you for the link to the original 24 week DPZ papers. I looked at the MMSE graph on page 140. The placebo MMSE is in a constant and increasingly steady decline from 6 weeks to 24 weeks. DPZ starts a steady decline in efficacy from 12 to 24 weeks. Comparing this graph with yesterdays 31 week results show A2-73 is very effective with no MMSE decline at all at 31 weeks. A2-73 is definitely working and is very effective compared to the placebo graph and helps reduce the degradation of DPZ that is evident after 12 weeks. It is overwhelmingly obvious that A2-73 is very potent without DPZ. This is the kind of data that dado stated would attract the partnership of a BP. I can see why that's coming now. This data just destroyed DPZ.
Why not pre-market? I doubt they wait for 1:00 pm EDT for a PR. I see the PR released before market
The safety levels have been established, which sets the dose levels for Phase 2/3. Looks very good!
That's what's going on here
Followed by on Wed, Jul 27:
Safety and Efficacy 31 Week Data of Anavex 2-73 in a Phase 2a Study in Mild-Moderate Alzheimer’s Disease Patients
Metro Toronto Convention Centre Room: Hall D/E
1:00pm - 2:00pm
They're humping the jq_jt ID again. Last jq_dt begathon was the 3-day 4th of July weekend humping, resulting in AVXL shooting up another +35%. Here we are again and the jq_dt assignment is in: it's another weekend begathon, so look for another huge power upside run next week.
Did you make +40% today from .75 to 1.05? Or did you just pick your nose like a troll? The point being this is definitely not a dead stock.